LLY Options Signal Bullish Sentiment at $1100 Call, But Put Activity Warns of Volatility – Here’s How to Position for 2026

• LLY trading at $942.31, up 1.2% today
• Strong call open interest at $1100 strike for next Friday
• Put/call ratio at 1.20 suggests cautious optimism
• Earnings, new drug launches, and a major acquisition in play

Eli Lilly is in motion today. The stock is trading above its 200-day average and options traders are showing clear signs of optimism — but with a twist. The call-to-put imbalance and OTM strike levels tell a nuanced story. Here’s what traders need to know.

Call Dominance at $1100, But Puts Warn of Caution

Options traders are eyeing the $1100 call strike for next Friday as a major focal point. That’s not just a random number — it’s where 2973 contracts have open interest, the highest for any OTM call in the next week. This means a lot of investors are betting on a meaningful move above $1050–$1100. For now, the stock is trading at $942, so this call is deep OTM — but with LLY’s recent momentum, it might not stay that way for long.

On the put side, the largest open interest is at $400 (3321 contracts) and $800 (3135 contracts). These strikes are extremely bearish, suggesting a small but vocal segment of the market is hedging against a collapse in value. Given that LLY is a blue-chip healthcare name with a strong balance sheet, this put activity could be speculative or hedging from long-term holders ahead of earnings or regulatory news.

Block trading remains quiet today — no large whale moves to report — which keeps the focus on retail and institutional options positioning. That’s not always a bad thing. In a stock like LLY, where fundamentals are strong and earnings are up, a lack of block trading might just mean the market is moving with confidence, not panic.

Strong Earnings, Strategic Moves, and New Product Launches Are Driving Sentiment

LLY’s recent news has been a mixed bag of bullish and cautionary signals. The company just posted Q1 earnings above expectations, driven by Mounjaro — its top diabetes drug. That’s a major win. Then came the $4.2 billion acquisition of MedTech Innovations and a new AI-powered diabetes platform. These are strategic moves that speak to long-term dominance in a high-growth sector.

But there’s also a patent dispute with Novo Nordisk, regulatory questions in Europe over Mounjaro’s safety, and manufacturing delays that forced a revised 2026 guidance. These are not deal-breakers, but they do inject a layer of caution. The options market reflects this duality: lots of call buying for higher strikes, but also a put/call ratio above 1.20 — not extreme, but not neutral either.

Trade Ideas: Use $1100 Calls and $950 Puts for Leverage and Protection

Here’s a way to participate without overexposing yourself. If you believe the stock could break out after its recent earnings beat and Mounjaro’s new formulation hits the market, the LLY20260417C1100 call is a high-impact play. It’s OTM, but with LLY sitting at $942, and a bullish Kline pattern, a break above $1000 could make this a strong contender for a 20%+ move in the next week. Entry: $950–$960 if the stock holds above $934 (middle Bollinger Band) and the RSI continues to build momentum above 50.

For those looking to hedge or short-term trade against a potential correction, the LLY20260417P950 put could act as a safety net. It’s not ultra-deep OTM and would come into play if LLY drops below its 200-day MA (899) or hits the 30D support level (916). If you’re more bearish, the LLY20260417P800 is a deep play, but it’s more speculative and not for the faint of heart.

Volatility on the Horizon – Prepare for the Next Move

With LLY launching a new weight management drug in Q2, hosting an investor day in May, and facing a legal battle in the next few months, volatility is inevitable. The options market is pricing in a lot of that risk already — but not all of it. If earnings continue to beat and the Mounjaro expansion continues to roll out, the $1100 call could be the key to capturing a big move. On the other hand, a legal loss or regulatory delay could test the $916–920 support zone.

The message is clear: LLY is set up for a breakout — but with risk on the downside. Traders should watch the 30D moving average and the RSI closely. A break above $1000 could signal the start of a new phase for the stock, and the options market is already pricing that in.